A Multicenter, Open, Single Sequence Crossover Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, FK506E (MR4), Based Immunosuppressive Regimen in Stable Kidney Transplant Patients Converted From a Prograf Based Immunosuppressive Regimen
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 18 Feb 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
- 01 Jan 2008 Status changed from in progress to completed.
- 24 Oct 2006 New trial record.